We stealth-launched $VRIL today, just five hours ago. No presales, no investors. Decentralization is at the core of everything we do, especially in an era of systemic shutdowns. Eli Lilly’s campaign against peptides has reached a boiling point. Peptide-related platforms and information are increasingly facing restrictions, censorship and regulatory pressure. After experiencing massive delivery issues earlier this year, we began exploring how DeSci (Decentralized Science) could make research more open, accessible and resilient. Since then, we’ve been building toward that vision. We became the only peptide marketplace worldwide operating exclusively on crypto payments. Now, it’s time for the next chapter. The gates to Hyperborea are open. A hidden world beyond the reach of bureaucracy, where researchers, lab rats and degenerates come together to explore vril, the mythical elixir of life. Our thesis is simple. Pharmaceutical research can become more efficient through agentic AI, open collaboration and decentralized participation, provided experimentation remains grounded in scientific rigor and safety. To make this vision possible, we needed strong foundations. $VRIL is that foundation. We’re reorganizing our entire business around the token, aligning the value generated by our venture with its ecosystem. That includes the value generated by our marketplace. Next, we’re introducing VRIALS (vril trials) on vrilpeptides.com, with incentives designed to support community participation, research and experimentation. The long-term vision is to accelerate discovery, develop new peptide products and build a distribution ecosystem directly through our own platform. This is our attempt to build the first crypto-native, full-circle peptide brand, combining AI, DeSci, crypto and community-driven research into one ecosystem. This is only the beginning. Welcome to Hyperborea. ⚡️